Latest Kaiser Health News Stories
Muchas farmacias no saben que los CDC han autorizado la cuarta dosis de la vacuna contra covid para personas con sistemas inmunes comprometidos.
A KHN reporter had written for years about the people left behind by the absurdly complex and expensive U.S. health care system. Then he found himself navigating that maze as he tried to get his insulin prescription filled.
The Centers for Disease Control and Prevention quietly changed its guidance to allow an extra shot in certain cases, but some pharmacy personnel are confused about who is eligible.
The top 12 states using antibody therapies produced by Regeneron and Lilly — which research shows don’t work against the omicron variant — include several Southern states with some of the nation’s lowest vaccination rates, but also California, which ranks among the top 20 for fully vaccinated residents.
Just 18% of 5- to 11-year-olds are fully vaccinated, with rates varying significantly across the country, a KHN analysis of federal data shows. Pediatricians say the slow pace and geographic disparities are alarming, especially against the backdrop of record numbers of cases and pediatric hospitalizations.
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
On Jan. 1, California started buying prescription drugs for its nearly 14 million Medicaid enrollees, a responsibility that had primarily been held by managed-care insurance plans. State officials estimate California will save hundreds of millions of dollars by flexing its purchasing power, but some health clinics expect to lose money.
Predominantly Black and Hispanic urban areas are more likely than white neighborhoods to see local pharmacies close and are more likely to be pharmacy deserts. In Chicago, one pharmacist is bucking the trend, operating the drugstore his father opened in the 1960s in a Black neighborhood.
Sen. Joe Manchin (D-W.Va.) dealt a blow to congressional efforts to pass President Joe Biden’s domestic agenda bill, forcing Democrats to regroup starting in 2022. Meanwhile, the omicron covid variant spreads rapidly in the U.S., threatening the stability of the nation’s health care system. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more, plus a look back at the year in health policy. Also this week, Rovner interviews Ceci Connolly, president and CEO of the Alliance of Community Health Plans.
Stores like Walmart and Shopko opened pharmacies in small towns, either buying out the local pharmacy or driving it out of business. What happens when those chains later withdraw, leaving communities with no pharmacy?
Independent pharmacists who want to retire often have trouble attracting new pharmacists to take over their practices, particularly in rural areas. That can cause smaller towns to lose their pharmacies. With many pharmacists near retirement, the problem may only get worse.
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals — loudly — that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
La administración Biden ha destinado $30 millones a programas de reducción de daños por adicciones. Pero defensores dicen que la principal barrera es que la naloxona sigue siendo de venta bajo receta.
Harm-reduction groups say that requiring a doctor to sign off on their orders of the overdose reversal drug is one of the biggest barriers they face in obtaining the lifesaving medication.
Last week, on the same day the Supreme Court heard a case that could overturn Roe v. Wade, the landmark ruling on abortion rights, Texas enacted a law that creates criminal penalties for anyone who prescribes medication abortions via telehealth or mail.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
The promising antiviral drugs to treat covid can halt hospitalizations and deaths, but only if they’re given to patients within three to five days of their first symptoms, a narrow window many people won’t meet. Here’s why.
Federal health officials appear poised to extend a recommendation for covid boosters to all adults, following moves by some governors and mayors to broaden the eligible booster pool as caseloads rise. Meanwhile, the Food and Drug Administration finally has a nominee to head the agency: former FDA chief Robert Califf. And Medicare premiums for consumers will likely rise substantially in 2022, partly due to the approval of a controversial drug to treat Alzheimer’s disease. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann, host of the “An Arm and a Leg” podcast.
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.
Fabricantes de medicamentos se niegan a ofrecer descuentos a miles de farmacias contratadas por los hospitales, diciendo que el programa ha crecido más allá de su uso previsto.